Point72 DIFC Ltd Invests $29,000 in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Point72 DIFC Ltd bought a new stake in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 49,820 shares of the company’s stock, valued at approximately $29,000.

Several other hedge funds also recently added to or reduced their stakes in CTXR. Vanguard Group Inc. lifted its holdings in shares of Citius Pharmaceuticals by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock valued at $6,286,000 after buying an additional 104,889 shares during the period. Arkadios Wealth Advisors lifted its holdings in Citius Pharmaceuticals by 50.0% in the second quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock valued at $88,000 after acquiring an additional 50,000 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in Citius Pharmaceuticals by 88.5% in the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after acquiring an additional 32,686 shares during the period. 16.88% of the stock is owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Stock Performance

Shares of Citius Pharmaceuticals stock opened at $0.52 on Monday. The firm has a 50-day simple moving average of $0.67 and a two-hundred day simple moving average of $0.70. Citius Pharmaceuticals, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $1.07. The company has a market cap of $94.29 million, a P/E ratio of -2.17 and a beta of 1.60.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Equities research analysts forecast that Citius Pharmaceuticals, Inc. will post -0.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, EF Hutton Acquisition Co. I raised shares of Citius Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 15th.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.